Eficacia y seguridad del uso profiláctico de emicizumab en pacientes adultos con hemofilia A con presencia de anticuerpos inhibidores del factor VIII, que fracasan o no son candidatos a la terapia de inmunotolerancia / Efficacy and safety of the prophylactic use of emicizumab in adult patients with hemophilia A with the presence of inhibitory antibodies to factor VIII, who fail or are not candidates for immunotolerance therapy
Lima; IETSI; jun. 2023.
Non-conventional
in Spanish
| BRISA/RedTESA
| ID: biblio-1553041
Responsible library:
BR1.1
Subject(s)
Full text:
Available
Collection:
Tematic databases
Database:
BRISA/RedTESA
Main subject:
Factor VIII
/
Hemophilia A
Type of study:
Health technology assessment
Limits:
Humans
Language:
Spanish
Year:
2023
Document type:
Non-conventional
